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Anticancer metallohelices: nanomolar potency and high
selectivity‡
Rebecca A. Kaner,a,b Simon J. Allison,c Alan D. Faulkner,a Roger M. Phillips,*c David I. Roper,e
Samantha L. Shepherd,c Daniel H. Simpson,a, e Nicholas R. Waterfieldd and Peter Scott*a
A range of new helicate-like architectures have been prepared via highly diastereoselective self-assembly using readily
accessible starting materials. Six pairs of enantiomers [Fe2L3]Cl4.nH2O (L = various bidentate ditopic ligands NN–NN) show
very good water solubility and stability. Their activity against a range of cancer cell lines in vitro is structure-dependent and
gives IC50 values as low as 40 nM. In an isogenic pair of HCT116 colorectal cancer cells, preferential activity was observed
against cell lines that lack functional p53. Selectivity is also excellent, and against healthy human retinal pigment epithelial
(ARPE19) and lung fibroblast (WI38) cells IC50 values are nearly three orders of magnitude higher. Cisplatin is unselective in
the same tests. The compounds also appear to have low general toxicity in a number of models: there is little if any
antimicrobial activity against Methicillin-resistant Staphylococcus aureus and Escherichia coli.; Acanthamoeba polyphaga is
unaffected at 25 μg ml-1 (12.5 μM); Manduca sexta larvae showed clear evidence of systemic distribution of the drug, and
rather than any observation of adverse effects they exhibited a significant mean weight gain vs controls. Investigation of
the mode of action revealed no significant interaction of the molecules with DNA, and stimulation of substantial cell death
by apoptosis.
Introduction
The main purpose of current anticancer therapies is to
eradicate tumour cells without damaging overall patient
health. However, side effects limit the dosage of
chemotherapeutic drugs which may be safely applied, and as a
result, cancer cells often remain. This leads to poor outcomes
in the clinic and the evolution of drug-resistant tumours. 1
Hence, while the potency of a drug is a very important
consideration, drug selectivity towards cancer cells is key to
ensuring both safety and effectiveness. 2 While we might hope
that more effective cancer chemotherapies would come from
drugs designed to address specific biomolecular targets, 2 this is
far from uniformly the case.3 Such drugs may be too targeted
since tumours can circumvent the blockade of a specific
pathway by switching to another – so-called tumour plasticity. 4
Compounds with polypharmacology (action against multiple
targets) are thus currently of considerable interest to the
pharmaceutical industry. This coincides with the resurgence of
phenotypic drug discovery,5-7 where the targets of a drug are
established after the observation of the useful biological
effect. This strategy has led to a disproportionately high
number of first-in-class drugs with novel mechanisms of action
(1999-2008)8,9 The accompanying challenge for synthetic
chemistry is to discover, perhaps without reference to some
specific biomolecular target, new classes of drug candidates
which are both potent and selective.
Lehn recognized the potential of helicates in medicinal
chemistry,10 and this was borne out in early studies,
particularly in the area of cancer.11-15 We have argued,16
however, that in order for helicates to be capable of
translation to the clinic a number of criteria need to be
addressed: optical purity and stability, solubility and chemical
stability in water, availability on a practical scale, and synthetic
diversity. Our recent work has attempted to address these
matters17 using a new strategy whereby the absolute
configurations of individual metal centres are controlled 18 and
linked together to form the prototype helicate-like
architectures of fig. 1. Of these flexicates, 19 [Fe2L13]4+ contains
a diamine linker while [Fe2L2a3]4+ is based on a dialdehyde.19
Promising results were reported in a number of disease
areas,16, 19-21 including good activity against a range of cancer
cell lines.20 Here we report the discovery of a new series of
highly potent (40 nM) anticancer compounds of the
dialdehyde class related to [Fe2L2a3]4+ that preferentially kill
cancer cells that lack functional p53, are nearly three orders of
magnitude less toxic to healthy human cell lines tested and
have low toxicity to microbes, amoeba and caterpillar larvae.
Fig. 1. Structure of flexicates [Fe2L13]4+ and [Fe2LA3]4+.19
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While DNA does not appear to be the target, the compounds
are triggering significant apoptotic cell death as part of their
mode of action.
Results
Synthesis of ligands and ZnII systems
The dialdehyde units of Fig. 2(a,b) include various linker
rigidities and orientations designed to probe structural viability
and biological activity. They were synthesized via simple
etherifications of 5-hydoxypicolinaldehyde. 22
Treatment with Zn(ClO4)2.6H2O and (R)-1-phenylethan-1-
amine, in appropriate proportions, led to the rapid self-
assembly of the bimetallic flexicates in acetonitrile solution at
ambient temperature. For the majority of these new Zn II
complexes NMR spectra indicated that within the limits of the
experiment single diastereomers were formed (vide infra).
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Fig. 2. (a) Synthesis of new flexicates; (b) linking groups used in this study; (c) Sections
of 1H NMR spectra of ΛZn-[Zn2L2e3][ClO4]4.4H2O at 253 – 353 K in d3-acetonitrile showing
the higher equilibrium population of a minor asymmetric conformer at higher
temperatures.
The sole exception was the 1,3-phenylene system ΛZn-
[Zn2L2e3][ClO4]4.4H2O, which gave more complex 1H NMR
spectra [Fig. 2(c)]. At 253 K the phenethylamine methyl group
doublet region 1.4-1.7 ppm contains one more intense doublet
and two broader signals in the ratio ca 10:1:1. The proportion
of the minor species increases with temperature and the
resonances sharpen somewhat, such that by 313 K two of the
smaller doublets corresponding to the minor species are
relatively sharp and resolved while a third overlaps with the
main resonance. By 353 K the smaller peaks had again
broadened considerably and the ratio of the two sets of
resonances was ca 10:9. The imine region (8.5 – 7.6 ppm)
behaved in a corresponding manner (253 K, three peaks in
ratio 10:1:1:1; 353 K, ratio 10:3:3:3). These observations are
consistent with the presence of two species – one of high-
symmetry and one low – in thermodynamic equilibrium (ratio
ca 1:0.3 at low temperature, increasing to almost 1:1 at high
temperature) but with the involvement of other related
conformers particularly at higher temperatures. The processes
leading to the observed NMR behaviour may correspond to
exchange between these conformers, or indeed between
isostructural low symmetry species. While the spectra are not
sufficiently well resolved to determine kinetic parameters, we
sought to investigate this molecular system by computational
means.
Computational studies
Following extensive searching, six conformers of ΛZn-[Zn2L2e3]4+
were located and minimised [fig. 3]. These fell into two classes:
those where the three m-xylenyl groups were oriented away
from the central cavity i.e. exo, and those where one such
group was oriented endo. No conformers were observed in
which two or three m-xylenyl groups were oriented into the
cavity – this caused too much torsional and steric strain.
Structure endo1 was found to be the lowest in energy, the
next lowest being endo2 (ca +5 kcal) which differs only in the
fold of one of the linkers. For these structures the Zn-Zn
distances are ca 11.7 and 11.8 Å respectively. The structure
exo1 (+7 kcal) has a large central cavity but a similar Zn-Zn
distance (11.8 Å). The structure exo2 (+8 kcal) has a
considerably shorter Zn-Zn distance at ca 9.5 Å with
accompanying concertinaed fold. Furthermore, higher energy
conformers exo3 and exo4 differed principally in how the m-
xylenyl groups folded towards each metal centre. Both were
found to have a short Zn-Zn distance of 9.4 and 9.5 Å
respectively.
While prediction of an equilibrium population from the
above calculations is complicated by statistical and entropic
contributions from the total number of possible structures and
the differences in structural flexibility, the detection of two
distinct structural classes is clearly consistent with
observations in solution.
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Relative energy /kcal Zn-Zn distance /Å Relative energy /kcal Zn-Zn distance /Å Relative energy /kcal Zn-Zn distance /Å
endo1 exo1 exo3
0 11.7 24.8 9.5 12.4 9.4
endo2 exo2 exo4
12.4 9.4 24.8 9.5 24.8 9.5
Fig. 3. DFT Calculated structures, relative energies (compared to endo1) and Zn-Zn distances of the six conformational isomers of ΛZn-[Zn2L2e3][ClO4]4. c) Linear decay of ln(ε) at 540 
nm (corresponding to MLCT band) of [Fe2L2c3]Cl4 (0.03 mM in 0.2 M HCl).
We propose that the species detected by NMR displaying high
symmetry (D3) comprises exo conformations while the
asymmetric (C1) species is endo. Examination of the structures
indicates that the barrier to conversion within the exo or endo
manifolds would be low since it would involve relatively simple
concertina-type processes, but conversion between exo and
endo conformations requires the rotation of the m-xylenyl
linker through a strained, high energy transition state.
Synthesis of water soluble compounds
Pairs of water-soluble Fe II flexicate enantiomers [Fe2Ln3]Cl4 (n =
2b-2e) were synthesised in high yield by heating the
appropriate dialdehyde linker with either (R)- or (S)-1-
phenylethan-1-amine and FeCl2 in methanol. 1H-NMR spectra
were similar though slightly broader than the analogous Zn II
perchlorate complexes and are consistent, along with 13C-NMR
[Fig. 4 and ESI] and circular dichoism spectra (ESI) with the
presence of single, stable, non-racemising diastereomers in
solution, although unsurprisingly [Fe 2L2e3]Cl4 exists as a similar
mixture of conformers to the Zn analogue above. The
complexes gave excellent electrospray mass spectrometry data
e.g. ΛFe-[Fe2L2c3]Cl4 gave a strong peak at m/z 420.17 Da for the
tetracationic ion. The formula weights of the panel of
complexes, including levels of hydration, were determined by
correlation of NMR, IR, thermogravimetric and elemental
analyses (See ESI). The p-xylenyl system [Fe2L2f3]Cl4 displayed
poor solubility in water and methanol and could not be fully
characterised.
Stability in aqueous media
Absorbance spectra indicated that little decomposition of the
flexicates occurred in water at pH 7 over weeks, but half-lives
for decomposition could readily be recorded in hydrochloric
acid (0.2 M) via the 540 nm MLCT absorbance band of the
complex. Even under such conditions, first order kinetic plots
gave t1/2 values in the region 10-20 h. This very favourable
aqueous stability of flexicates probably arises from the
presence of extensive (hydrophobic) -stacking.23
Fi
g. 4. 1H and 13C{1H}. .  NMR spectra of ΛFe-[Fe2L2c3]Cl4.9H2O at 298 K in d4-methanol; see
Fig.2 for key.
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Fig. 5. IC50 values of cisplatin (Pt, white) and flexicates [Fe2Ln3]Cl4 (n = 2a-2e) (ΛFe - dark grey, ΔFe - light grey) against a) MDA-MB-468, b) HCT116 p53+/+, c) HCT116 p53-/-, d) ARPE19
and e) W138 cells over 96 h; dotted line highlights the relative sensitivity of test compounds compared to cisplatin, f) in vitro selectivity index (IC50 ARPE19 / IC50 HCT116 p53-/-) -
broken line at selectivity index = 1 represents no difference in IC50 between tumour and normal cells – note log scale on y axis.
Biological Activity & Selectivity
Cytotoxicity
The activities of the new compounds and cisplatin were
investigated in human tumour cell lines: (a) MDA-MB-468
(human epithelial breast adenocarcinoma); 24 (b) HCT116
p53+/+ and (c) HCT116 p53-/-.25 The HCT116 p53+/+ and HCT116
p53-/- cancer cells are human colorectal cancer cell lines that
are genetically identical (isogenic) except for the presence or
absence of functional p53.25 These were chosen to enable
screening of the effects of p53 status as the loss of p53
function is common genetic event in patient tumours and is
strongly associated with increased resistance to many
conventional chemotherapeutic agents. 25, 26 In the cisplatin-
sensitive (2.5 ± 0.5 µM) MDA-MB-468 cells, the new flexicates
showed a range of activities [fig. 5(a)], with enantiomers of the
glycol-bridged [Fe2L2b3]Cl4 being very potent (0.2 ± 0.1 µM); an
order of magnitude more so than cisplatin. Against HCT116
p53+/+ cells [fig. 5(b)] while cisplatin had a similar activity (3.5 ±
1.5 M) as in the MDA-MB-468 cells, the flexicates were still
more potent, with several examples having sub-micromolar
activity, e.g. [Fe2L2e3]Cl4 0.4 ± 0.1 µM), and some significant
enantiomeric differences were observed. Against HCT116 p53 -
/- cells, cisplatin showed less activity (8.1 ± 1.8 µM) than for
HCT116 p53+/+ cells (3.5 ± 1.5 M) consistent with the
increased resistance of cancer cells lacking p53 to many
standard chemotherapeutic agents, while some of the
flexicates were extremely active (2a, 2c) with IC50 values in the
nanomolar range e.g. Fe-[Fe2L2c3]Cl4 (40 ± 3 nM) [fig. 5(c)]. Of
particular note, flexicates ΛFe-[Fe2L2c3]Cl4 and Fe-[Fe2L2c3]Cl4
were both ~9-fold more active against HCT116 p53 -/- cancer
cells than their genetically identical p53 +/+ counterparts [fig.
5b,c; see SEI].
Toxicity in healthy human cells
The most active flexicates in HCT116 p53-/- cancer cells (2a, 2c),
along with cisplatin, were investigated in human non-cancer
retinal pigment epithelial cells (ARPE19) 27 and normal lung
fibroblasts (WI38) [Fig. 5(d)-(e)]. These are healthy human cells
with a stable diploid karyotype which senesce after multiple
passaging as is characteristic of non-cancer cells. 27 In Fig. 5(f)
we depict an in vitro selectivity index (SI) which compares the
activity of these compounds in ARPE19 and HCT116 p53 -/- cells.
While for cisplatin SI was found to be significantly less than 1,
meaning that it is actually more toxic to these healthy cells
than it is to the cancer cells, the flexicates tested gave SI
substantially higher, and for Fe-[Fe2L2c3]Cl4 SI = 836 ± 280. This
excellent selectivity prompted us to investigate the toxicity of
the compounds against a number of organisms.
Toxicity to microbes
The compounds were screened against cultures of the gram-
positive bacterium Methicillin-resistant Staphylococcus aureus,
USA300 JE228, 29 (MRSA) and the gram-negative Escherichia
coli, TOP10 (E. coli).30 Kanamycin30 was used as a positive
control.
The new flexicates had very modest antimicrobial activity
(Table 1) or did not significantly inhibit microbial growth at
concentrations well over 3 orders of magnitude higher than
the IC50 values observed in cancer cells.
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Table 1.MIC values for kanamycin and flexicates [Fe2Ln3]Cl4 (n = 2a-2e) against MRSA
and E. coli, over 20 h at 37°C in Mueller-Hinton broth. The approximate concentrations
in M are included for comparison with IC50 data from cancer cell line testing.
Compound
MRSA MIC E. coli MIC
(μg ml-1) (μM) (μg ml-1) (μM)
Kanamycin 1 2 2 4
ΛFe-[Fe2L2a3]Cl4 64 35 >128 70
ΛFe-[Fe2L2b3]Cl4 128 70 >128 70
ΛFe-[Fe2L2c3]Cl4 128 70 >128 70
ΛFe-[Fe2L2d3]Cl4 >128 70 64 35
ΛFe-[Fe2L2e3]Cl4 64 35 128 70
Fig. 6. Relative weight ofManduca sexta larvae after treatment (7 d) with [Fe2L2a3]Cl4
(ΛFe - dark grey, ΔFe - light grey) compared to an untreated control.
Toxicity in amoebae andM. sexta larvae
We further tested the potential toxicity of these compounds
using a single cell protist organism, the well-established
amoeba model Acanthamoeba polyphaga. Concentrations of
2.5 g ml-1 (1.25 μM) and 25 g ml-1 (12.5 μM) showed no 
adverse effect on the amoeba development (see ESI) also
suggesting no broad-spectrum toxicity.
Oral and systemic toxicity of these flexicates was assessed
in neonate larvae of Manduca sexta.31 Caterpillars which had
ingested a solution of 25 µg ml -1 ([12.5 μM], [Fe2L2a3]Cl4 in
artificial diet for 7 d [Fe2L2a3]Cl4 showed comparable weight
gain to controls suggesting no oral toxicity and no adverse
effect on feeding behaviour (Fig. 6). Interestingly the larvae
exhibited an increased mean weight gain of approximately
30% (P<1). Also we noted that larvae that ingested the
flexicate solutions turned a bright purple colour over the
course of the assay, suggesting that these compounds were
persisting in the insect and not being rapidly metabolized or
excreted.
Systemic toxicity was further tested by injection of 50 g
(0.25 μM) of the compounds directly into the hemocoel of 
cohorts of 5th instar larvae (n = 3). The cohorts were then
allowed to continue feeding. Despite becoming purple, all
larvae proceeded to develop into the pupal diapause stage as
per the buffer control injections.
Mode of Action
The mode or modes of action of such a new and different
system will require intensive investigation and is likely to
involve multiple targets and pathways. Here, we describe two
preliminary studies towards this end.
Denaturation of ct-DNA
Fig. 7. Effect on Tm of linear ct-DNA (DNA, white) from interactions [Fe2Ln3]Cl4 (n = 2a-
2e) (ΔFe - light grey, ΛFe - dark grey) in 1mM Trizma base (10 base pairs of DNA to 1
flexicate complex).
We have previously concluded that the induction of DNA
damage is not involved in the mode of action of earlier
flexicates, despite particular examples binding in a cell free
environment.20, 32, 33 We investigated the effect that the new
flexicates had on the denaturation temperature (Tm) of ct-DNA
to screen for any indications of DNA binding.
Isolated ct-DNA (0.5 mg ml -1) was mixed with each flexicate
(7.5 µM) in buffered conditions (10 mM Tris, 1 mM EDTA at pH
7.0), to give 10 bases: 1 flexicate complex, and the absorbance
at 260 nm between 25°C and 90°C was recorded (0.4 °C min -1).
Tm for each experiment was calculated from the first derivative
of a Boltzmann sigmoidal fit of the plot of absorbance versus
temperature.
Tm of untreated ct-DNA (0.25 mg ml -1 in 10mM Tris, 1 mM
EDTA at pH 7.0) was measured to be 68.3 ± 0.5°C. Most of the
new flexicates had no significant effect on the denaturation of
ct-DNA (Fig. 7); the small (T ca 1°C) reduction for L2e
enantiomers can be ascribed to an electrostatic effect. 34 We
are therefore satisfied that DNA is unlikely to be the target of
this panel of compounds.
Induction of cell death by apoptosis
The chemosensitivity observed could be due to cytostatic or
cytotoxic effects, and cell death can occur by several different
mechanisms. These include programmed cell death by
apoptosis, inflammatory necrosis, autophagy or ‘self-eating’,
necroptosis and pyroptosis.35 One of the hallmarks of cancers
is the evasion of apoptosis, thus enabling the long-term
survival and proliferation of cancer cells. 36 We thus
investigated whether the most active flexicates are stimulating
apoptotic death in cancer cells as part their mode of action.
HCT116 p53+/+ cancer cells (24 h post-seeding) were
incubated in fresh media containing flexicate or no flexicate
(control) and were then analysed after 48 h for levels of
apoptosis and necrosis. As cells start to undergo apoptosis,
one of the first cellular changes is the externalisation of the
membrane protein phosphatidylserine (PS). This can be
detected and quantified by fluorescently labelled annexin V 37,
38 which can selectively bind externally exposed PS but is
membrane-impermeable. This enables cells in the early stages
of apoptosis to be distinguished from necrotic cells and cells in
the late stages of apoptosis both of which have lost membrane
integrity and will therefore also stain with the membrane-
impermeable DNA stain propidium idodide. 39
Page 5 of 8 Chemical Science
Ch
em
ica
lS
cie
nc
eA
cc
ep
ted
Ma
nu
sc
rip
t
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
6 
O
ct
ob
er
 2
01
5.
 D
ow
nl
oa
de
d 
on
 2
7/
10
/2
01
5 
15
:5
2:
03
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
DOI: 10.1039/C5SC03677A
ARTICLE Journal Name
6 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
Please do not adjust margins
Please do not adjust margins
Fig. 8. Induction of apoptosis in HCT116 p53+/+ cancer cells by 48h treatment with the
indicated flexicates. Fold change shown relative to basal apoptotic levels in untreated
HCT116 control cells.
Flexicates ΛFe-[Fe2L2a3]Cl4 and Fe-[Fe2L2a3]Cl4 were tested and
both induced significant levels of apoptosis that were ~2.6 fold
(ΛFe-[Fe2L2a3]Cl4) and ~4.4 fold (Fe-[Fe2L2a3]Cl4) above
background control levels in the HCT116 cancer cells at 48h
(Fig. 8). A significant proportion of late apoptotic/necrotic cells
were also detectable by 48h, with levels ~2.3-2.5 fold above
background control levels (Fig. 8). These preliminary
investigations indicate induction of apoptosis by these new
flexicates as part of their mode of action.
Experimental
Synthesis
(E)-5,5'-(but-2-ene-1,4-diylbis(oxy))dipicolinaldehyde (0.13 g, 0.44 mmol)
and (R)-1-phenylethan-1-amine (0.11 g, 0.88 mmol) were dissolved in
acetonitrile (10 ml) with ZnII perchlorate hexahydrate (0.11 g, 0.29 mmol)
and the solution was stirred at ambient temperature for 20 h. Ethyl acetate
was added drop-wise to cause precipitation of a white crystalline solid, ΛZn-
[Zn2L2c3][ClO4]4.10H2O. Yield 0.214 g, 57%. 1H NMR (400 MHz, 298 K,
CD3CN) δH 8.06 (6H, s, CHN), 7.49 (6H, dd, 3JHH = 8.5 Hz, 4JHH = 3.5 Hz),
7.36 (6H, d, 3JHH = 8.5 Hz), 7.14 (6H, d, 3JHH = 3.5 Hz), 7.09 (6H, t, 3JHH =
8.0 Hz), 6.95 (12H, t, 3JHH = 7.5 Hz), 6.64 (12H, d, 3JHH = 7.0 Hz, Ar), 6.12
(6H, m), 5.38 (6H, q, 3JHH = 6.5 Hz, CH), 4.64 (12H, s, CH2), 1.61 (18H, d,
3JHH = 6.5 Hz). 13C{1H} NMR (101 MHz, 298 K, CD3CN) δC 161.8 (CHN),
159.6, 142.0, 139.9, 139.4, 132.3 (Ar), 129.7 (CH), 129.4, 128.5, 126.4,
122.7 (Ar), 69.7 (CH2), 64.7 (CH), 23.6 (CH3). MS (ESI) m/z 411 [Zn2L3]4+.
IR υ cm-1 2976 w, 1570 m, 1316 m, 1225 m, 1082 s, 762 w, 703 m, 653 m.
Elemental analysis found (calculated for C96H96Cl4N12O22Zn2.10H2O) % C
51.08 (51.88), H 4.82 (5.26), N 7.38 (7.56).
(E)-5,5'-(but-2-ene-1,4-diylbis(oxy))dipicolinaldehyde (0.1 g, 0.32 mmol)
and (R)-1-phenylethan-1-amine (0.08 g, 0.63 mmol) were dissolved in
methanol with FeII chloride (0.03 g, 0.21 mmol). The solution was stirred at
reflux (75°C) for 48 h and all volatiles were removed under reduced
pressure to yield a dark purple solid, ΛFe-[Fe2L2c3]Cl4.9H2O. Yield 0.388 g,
97%. 1H NMR (400 MHz, 298 K, MeOD) δH 8.80 (6H, s, CHN), 7.47 (6H,
s), 7.13 (6H, t, 3JHH = 7.0 Hz), 7.04 (12H, t, 3JHH = 7.0 Hz), 6.64 (12H, d,
3JHH = 7.0 Hz), 6.44 (6H, s), 6.05 (6H, s, Ar), 5.26 (6H, q, 3JHH = 6.0 Hz,
CH), 4.65 (12H, s, CH2), 4.59 (6H, br s, CH), 1.99 (18H, d, 3JHH = 6.0 Hz,
CH3). 13C{1H} NMR (101 MHz, 298 K, MeOD) δC 171.0 (CHN), 158.8,
152.5, 144.8, 141.7, 131.2, 130.1, 129.8, 128.5, 125.5 (Ar), 121.0 (CH),
70.0 (CH2), 69.6 (CH), 26.1 (CH3). MS (ESI) m/z 406 [Fe2L3]4+, 505
[L+H].IR υ cm-1 3352 br s, 2970 br s, 1589 s, 1557 w, 1488 w, 1381 m,
1299 s, 1067 m, 1028 m, 760 m, 699 s, 562 w. Elemental analysis found
(calculated for C96H96Cl4Fe2N12O6.9H2O) % C 59.92 (59.76), H 5.84 (5.96),
N 8.63 (8.71).
Molecular modelling
Models of a number of possible conformers of ΛZn-[Zn2L2e3][ClO4]4 were
constructed and optimised. Starting points for geometry optimisations were
taken from crystallographic data. Monometallic structures were first
optimised using the B3LYP-D3(BJ)40 functional and the 6-31g* basis set,
with convergence criteria of 0.0001 a.u. as implemented in the Firefly
quantum chemistry package,41 which is partially based on the
GAMESS(US) source code.42 Bimetallic systems were optimised using
ligand field molecular mechanics (LFMM)43 as implemented in the
DommiMOE program,44 before being annealed at 500 K for 1 ns prior to
re-optimisation. Single point energy calculations of all structures were
performed using the B3LYP-D3(BJ)40 functional and the deff2-TZVP basis
set with energy convergence criteria of 0.0001 a.u. as implemented in the
Firefly quantum chemistry package.41 The calculations were conducted by
employing the RIJCOSX approximation with SCF convergence criteria set
to ‘tight’, both of which are defined internally as part of the ORCA DFT
quantum chemistry package.45 Where relevant, acetonitrile solvate
correction was performed using the conductor-like screening model
(COSMO)46 as implemented in ORCA.45
Biological Activity
MIC values were established using a macrobroth dilution method in cation-
adjusted Müller-Hinton (MH) broth. 96-well plates (200 µl of 128 µg ml-1 (64
μM) complex in MH broth, diluted 2n µg ml-1, inoculated with each bacterial
strain (103 cfu ml-1) were sealed and growth was monitored over 20 h at
37°C with an iEMS 96-well plate reader (see ESI).
IC50 values were determined by incubating cells in 96-well plates (2.0 ×
103 cells/well) for 24 h at 37°C, 5% CO2 prior to drug exposure.
Compounds were added (100 µM – 5 nM in cell medium) for a further 96 h.
3-(4,5-Dimethylthiazol-1-yl)-2,5-diphenyl tetrazolium bromide solution (0.5
mg ml-1, 20 µl per well) was added for a final 4 h. Upon completion all
solutions were aspirated, dimethyl sulfoxide (150 μl) was added and 
absorbance (540 nm) was recorded with a Thermo Scientific Multiskan EX
microplate photometer.
Oral toxicity was established by feeding cohorts of Manduca sexta31 one-
day-old neonate larvae with each flexicate (25 µg ml-1 in artificial wheat
germ diet) for 7 d at 28°C and weighing to assess growth rate. Systemic
toxicity assays47 were conducted by injecting an ethanol (70% v/v)
swabbed region of first day fifth instar M. sexta larvae with each flexicate
(0.5 mg ml-1 [0.25 μM] in PBS), before allowing them to continue feeding
for 7 d at 28°C, using physical stimulus to assess their status.
Mode of Action
Denaturation of ct-DNA was measured by mixing ct-DNA (0.5 mg/ml,
7.5×10-5 per base, as determined by absorbance at 200 nm) with each
complex (7.5 µM) in buffered conditions (10mM Tris, 1 mM EDTA at pH
7.0) to give 10 base: 1 complex. The absorbance at 260 nm as a function
of temperature (every 1°C, 25-90°C) was measured in a 1 cm masked
quartz cuvette at a rate of 0.4°C min-1 and run in triplicate. Tm was
calculated from the first derivative of a Boltzmann sigmoidal fit of the plot of
absorbance at 260 nm against temperature for each complex.
Induction of apoptosis was determined by incubating HCT116 p53+/+
cells (5×105 cells/flask, 10ml complete RPMI-1640 medium) for 24h at
37°C in 5% CO2, before treating with each flexicate (20μM in fresh
complete media for 48h) or fresh media containing no drug (control). The
supernatant containing any non-adhered, floating cells was then collected
and pooled with cells harvested by trypsinisation. This pooled single cell
suspension was washed twice with PBS and incubated with propidium
iodide and Annexin-V-FLUOS (Roche) to stain apoptotic cells in
accordance with the manufacturer’s instructions. The proportion of early
stage apoptotic cells and late stage apoptotic/necrotic cells were then
quantified by flow cytometry as previously described. 37, 38
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Conclusions
Our approach to metallohelix assembly has allowed us to
generate a panel of biologically-compatible enantiomers
incorporating various bridging groups. This was possible
because in this so-called flexicate platform the
stereochemistry of the metal complex units is predetermined
very efficiently and largely independently of the bridges, and
by a mechanism that also provides water-compatibility. 23, 48 In
contrast, in a conventional “helication” approach the bridging
units are structure-determining, so a mechanism of
stereoselection would need to be designed for each example.
A further advantage of the flexicate platform is beginning to
emerge in that we may be able to develop asymmetric
molecules from symmetric ligands via the kinds of
conformational abnormalities caused by bridges that partially
oppose the predetermined stereochemistry e.g. L2e. We have
already shown that asymmetric (as opposed to merely chiral)
optically pure assemblies are available using directional
ligands.49 Further, this modular self-assembling system will
allow us to probe the effects of peripheral functionality and
lipophilicity.
The activity of these new assemblies against cancer cells is
strongly dependent on structure, with a range of potencies
from 30 μM to as low as 40 nM. The most active compound 
ΔFe-[Fe2L2c3]Cl4 shows a selectivity index (versus healthy cell
lines) approaching 103, demonstrating superiority over the
clinically used anticancer drug cisplatin in vitro (SI < 1). This
selectivity is substantiated in tests with various models;
bacteria and amoeba exposed to high concentrations were
essentially unaffected, and in Manduca sexta larvae, where
the systemic stability of the drug is evidenced, there is
arguably a pro-biotic effect i.e. the insects appear to thrive.
In respect of mechanism or mode of action, the lack of
binding to DNA indicates that this is unlikely to be the general
target in this panel. In fact only one early flexicate 19 ([Fe2L13]4+,
Fig. 1) in our growing library shows significant interactions with
nucleic acids, and while there are fascinating selectivities with
various motifs19, 32, 33 there is no DNA damage akin to that
induced by e.g. platinum drugs and alkylators.34, 49 Instead,
relevant examples of protein interaction and enzyme inhibition
have been characterised.21, 32 To achieve drug safety and
cancer selectivity, mechanistic classes which do not involve
induction of DNA damage are attractive, and this may well be
the source of the excellent selectivities we describe in this
manuscript. Mode of action studies indicate that these
compounds can induce substantial cell death by apoptosis
independent of any DNA damage. Extensive studies are now
required to understand how this complex process, normally
subverted in cancers, is induced by these compounds. The
above observations of remarkable selectivity alongside very
high potency and large enantiomeric differences are however
all consistent with a subtle mechanism involving the targeting
of oncogenic drivers.
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